Oncologic profile of maxillary odontogenic myxoma: A rare case

Reena Radhikapas Sad Sarkar

Abstract
Odontogenic myxoma (OM) is an ectomesenchyme derived neoplasm, almost exclusively found in jaws. This article presents a maxillary OM with a brief review of the molecular and proteomic antecedents of OMs, capturing its histopathogenesis.

Keywords: Ectomesenchyme, extracellular matrix, immunohistochemistry, odontogenic myxoma, proteomic analysis, stem cells

Introduction
Mucoid tumors of soft-tissue represents a heterogeneous group of lesions that exhibit significant differences in biological behavior, ranging from harmless to malignant neoplasms. As an osseous entity odontogenic myxomas (OMs) are found in the bones of the jaws and are considered slow growing tumors with potential for extensive bone destruction. With mandible being affected more than the maxilla, the premolar molar region of jaws are affected. Females are more affected. Radiographic features are described as small unilocular to large multilocular tumors that displace teeth or less frequently resorb roots of teeth.

A case of maxillary myxoma occurring in the maxilla of a 34-year-old female patient is described followed by molecular review with emphasis on histogenesis and biological behavior.

Case Report
A 34-year-old female patient approached the department for an opinion regarding a swelling in the left upper jaw. Past dental history revealed an episode of trauma 1 year back with a subsequent slow growing swelling in the posterior region of left maxilla when patient reported to the department, she had a bony hard non-tender diffuse swelling of approx. 2.5 cm × 2 cm on the left middle third of face obliterating the nasolabial fold. Intra-orally, the lesion obliterated the vestibule and extended from 23 to 26 regions. It was approx. 3 cm × 2 cm × 1 cm in dimension. Overlying mucosa showed no color change. The associated teeth showed grade 1 mobility. Orthopantamograph revealed a unilocular radiolucent lesion in 23 to 26 regions. Root resorption was observed. None of the teeth were absent in maxillary jaw. Missing teeth were 37 and 46. Fine needle aspiration failed to show any cellular yield.

An excisional biopsy harvested multiple small pieces of the lesional tissue. Gross specimen was yellowish white, glistening, gelatinous, lobulated mass. Histopathological examination revealed typical features of myxoma, with loosely arranged stellate or spindle shaped cells within a myxoid matrix. At places, tumor showed collagen fiber bundles. Islands of odontogenic epithelium were seen. The findings were found consistent with OM.

Figure 1: Intraosseous swelling extending from 23 to 26 region obliterating buccal vestibule
Although the incidences of recurrences are high, a 12 month asymptomatic follow-up has been recorded. [Figures 6 and 7]

Discussion

Myxoma of head and neck is a rare tumor.[3] The OM is a rare benign tumor that represents about 3% of all odontogenic tumors.[4] In Asia, Europe and America, relative frequencies between 0.5 and 17.7% have been reported. There is no gender predilection and it is seen in ages between 10 and
odontogenic mesenchyme may stain positively for s100. A minority of OM and enlarged follicles but not normal odontogenic mesenchyme may stain positively for s100 protein. The finding that myxomas did not contain s100 may help in differentiating myxomas from enlarged myxoid follicles. Neoplastic cells of myxomas were positively stained for transferrin, ferritin, alpha 1 antichymotrypsin, alpha 1 antitrypsin, s-100 protein, vimentin and actin. It’s a tumor of dual fibroblastic histiocyte origin and cells may be of myofibroblastic origin as described by Sivakumar et al. Ultrastructural studies show that the neoplastic spindle cells are fibroblast like cells called myxoblasts. They have the capacity to synthesize large quantities of mucopolysaccharides. The cells show positivity to vimentin, muscle specific actin.

OMs stained positive for Nestin in half of study cases of Fujita et al. It is also suggested to be involved in the differentiation from pulp cells to odontoblasts in odontogenic tumor. Nestin is the one of the cytoskeleton constituting intermediate filament. It’s a marker of neural stem cells or progenitor cells.

Mutations of Gs alpha gene are rarely if ever, associated with sporadic jaw myxoma tumourigenesis. Furthermore, a mutation in the protein kinase A regulatory subunit type 1A (PRKAR1A) has been reported. Both mesenchymal cells as well as islands of odontogenic epithelium expressed MIB1 (mind bomb homolog 1 Drosophila). The cells of odontogenic epithelium were positive for Bcl-2 and p53 in OMs of the jaws. PRKAR1A mutations have also been reported in OMs by Willems et al.

Nakano compared notch signaling among OM and ameloblastic fibroma. Notch is a receptor for inhibitory signals and has a role to play in cytodifferentiation. It governs neoplastic cell differentiation in mesenchymal tumors. The authors said that the developmental stage of myxoma tumor tissue is less advanced than ameloblastic fibroma. The tumor tissue is differentiated to levels as seen in cap stage. The rate of differentiation is closely related to clinical behavior.

Hyaluronic acid, which belongs to group of GAGs is the major contributor to the edematous appearance of the myxoid extracellular matrix (ECM). Their rigidity is responsible for the structural integrity of tissues facilitating diffusion of metabolites and cell migration. The exuberance of ECM protein, hyaluronic acid observed in vivo and in vitro strongly suggests that it has a definitive role in the local invasiveness of this neoplasm. Other ECM molecules expressed by these cells are fibronectin, type 1 collagen and tenascin. These investigations points out that human immature dental papilla stem cells bear a strong resemblance to OM cells. A high degree of matrix metalloproteinases 2 (MMP2) expression was found in cell lines derived from OM tumor.

Miyagi et al., also analyzed the expression and activity of miR-125a in odontogenic tumors. MiR-125a is a tumor suppressor that is frequently downregulated in cancers. They found that miR-125a expression was significantly lower in myxomas compared to other odontogenic tumors. This suggests a potential role for miR-125a in the pathogenesis of myxomas.

Bryant, in 1802, introduced the term myxosarcoma, which he described as a mucous transformation of round cell sarcoma, malignant and of large volume, usually attacking the omentum and skin. Furthermore, myxomas were described under the name of collenemas by Johannes Miller in 1838. In his 1858 article titled cellularpathologie, Rudolph Virchow introduced the term “myxoma” to describe a soft-tissue tumor, resembling the structure of the umbilical cord. OM was first described by Thoma and Goldman in 1947. There are two divisions observed those that are observed in jaw bones and those that are observed in soft-tissues of that area. It’s slow growing locally aggressive. In 1948, Stout labeled the myxoma as a true neoplasm.

This tumor has an extremely rare malignant version called odontogenic myxosarcoma.

The current knowledge of the OM still has significant gaps. One of them is related to the histogenesis of the odontogenic neoplasms. Majority of tumors occur in jaw bearing areas therefore the word odontogenic is prefixed to reflect its odontogenic origin. The resemblance to mesenchyme of developing tooth or the periodontal ligament suggests its odontogenic origin, loosely arranged in a soft, mucoid matrix composed of glycosoaminoglycans (GAGs). Hyperchromatic nuclei and mitotic figures are rare. The epithelial odontogenic rests that are found in the periodontal ligament surrounding teeth. Presently authors have started to hypothesise that myoblasts may have developed due to inductive effect of this odontogenic epithelium.

Myxoid changes in other neoplasms may mimic OMs. Such appearances may be found in myxoid neurofibromas, myxoid lipoma and chondromyxoid fibroma. Dental follicle or papillae, normal developmental structures removed in conjunction with unerupted or impacted teeth, may be misinterpreted as a myxoma.

A minority of OM and enlarged follicles but not normal odontogenic mesenchyme may stain positively for s100.
of matrix metalloproteinases 2 and 9 involved in tumor expression. MMP are zinc dependent enzymes that can degrade structural components of the ECM facilitating invasion of tumor cells through normal tissues. These authors investigated the capacity of the cells to penetrate bony trabeculae and their relation with ECM. Fibroblasts, odontoblasts and osteoblasts produce MMPs. They concluded that MMP 9 can lend invasive character to OM.[12]

Moreira et al., attempted to investigate methylation pattern in OM. Deoxyribonucleic acid methylation is an epigenetic change occurring during the transcription. Tumor suppressor genes in both OMs and dental pulps were investigated. They were cyclin dependent kinase inhibitor genes p16, p21, p27, p53 and RB1(retinoblastoma 1 gene). Cell cycle is dominated by interaction of cyclins and cyclin dependent kinases. Cyclin dependent kinase inhibitors are down-regulated cell cycle. Methylation of genes down-regulates protein expression and contributes to myxoma growth. p27, p53, RB1 showed hypomethylation in myxomas.[13]

García-Muñoz et al., stated that orosomucoid protein is immunomodulatory and angiogenic and therefore results in invasive behavior of OM. It is anti-inflammatory, anti-neutrophil, anti-complement. Presence of orosomucoid protein justifies classical mucoid appearance of the tumor. This protein was present in the cytoplasm of stellate and spindle tumor cells as well as in endothelial cells of large and small blood vessels. Expression of carbonic anhydrase I and glutathione S-transferase was down-regulated in OMs. Carbonic anhydrase was proposed to have affected the balance between bone resorption and apposition. Glutathione transferase when inactivated was leading to loss of protective mechanism against genome damage and tumor suppressor protein.[14]

The histogenesis of OM is poorly understood. It still remains a debatable matter. Myxomas of the head and neck are rare tumors. This case report canvasses a maxillary OM, which again is considered as a rarity. A review of the current proteomic, immunohistochemical concepts has been attempted to update our understanding about the neoplasm.

References

1. Li TJ, Sun LS, Luo HY. Odontogenic myxoma: A clinicopathologic study of 25 cases. Arch Pathol Lab Med 2006;130:1799-806.
2. Willems SM, Wiweger M, van Roggen JF, Hogendoorn PC. Running GAGs: Myxoid matrix in tumor pathology revisited: What’s in it for the pathologist? Virchows Arch 2010;456:181-92.
3. Escamilla FL. Odontogenic myxoma clinical case presentation. Rev Odontol Mex 2011;15:243-9.
4. LinYL, Basile JR. A case of odontogenic myxoma with unusual histological features mimicking a fibro-osseous process. Head Neck Pathol 2010;4:253-6.
5. Chrcanovic BR, do Amaral MB, Marigo Hde A, Freire-Maia B. An expanded odontogenic myxoma in maxilla. Stomatologija 2010;12:122-4.
6. Iezzi G, Piattelli A, Rubini C, Artese L, Fioroni M, Carinci F. MiB-1, Bcl-2 and p53 in odontogenic myxomas of the jaws. Acta Otorhinolarngol Ital 2007;27:237-42.
7. Miyagi SP, Maranduba OM, Silva Fde S, Marques MM. Dental pulp stem cells express proteins involved in the local invasiveness of odontogenic myxoma. Braz Oral Res 2012;26:139-44.
8. Lombardi T, Lock C, Samson J, Odell EW. S100, alpha-smooth muscle actin and cytokeratin 19 immunohistochemistry in odontogenic and soft tissue myxomas. J Clin Pathol 1995;48:759-62.
9. Sivakumar G, Kavitha B, Saraswathi TR, Sivapathasundharam B. Odontogenic myxoma of maxilla. Indian J Dent Res 2008;19:62-5.
10. Fujita S, Hideshima K, Ikeda T. Nestin expression in odontoblasts and odontogenic ectomesenchymal tissue of odontogenic tumours. J Clin Pathol 2006;59:240-5.
11. Nakano K. A study of recurrent giant odontogenic myxoma of the mandible with immunohistochemical examination of Notch. Oral Med Pathol 2008;12:53-6.
12. Miyagi SP, Hiraki KR, Martins MD, Marques MM. Expression of matrix metalloproteinases 2 and 9 in odontogenic myxoma in vivo and in vitro. J Oral Sci 2008;50:187-92.
13. Moreira PR, Cardoso FP, Brito JA, Batista AC, Gomes CC, Gomez RS. Hypomethylation of tumor suppressor genes in odontogenic myxoma. Braz Dent J 2011;22:422-7.
14. García-Muñoz A, Rodríguez MA, Bologna-Molina R, Cázares-Raga FE, Hernández-Hernández FC, Farfán-Morales JE, et al. The orosomucoid 1 protein (α1 acid glycoprotein) is overexpressed in odontogenic myxoma. Proteome Sci 2012;10:49.

How to cite this article: Sarkar RR. Oncologic profile of maxillary odontogenic myxoma: A rare case. Contemp Clin Dent 2013;4:374-7.

Source of Support: Nil. Conflict of Interest: None declared.